Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
STAT3 mutation
Cancer:
Myelodysplastic Syndrome
Drug:
Promacta (eltrombopag)
(
Thrombopoietin receptor agonist
) +
cyclosporin A microemulsion
(
Calcineurin inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
NCCN
Published date:
11/19/2021
Excerpt:
Myelodysplastic Syndromes: Patients generally ≤60 y and with ≤5% marrow blasts, or those with hypocellular marrows, PNH clone positivity, or STAT-3 mutant cytotoxic T-cell clones. IST includes equine ATG ± cyclosporin A ± eltrombopag.
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login